Company Overview and News

4
Icahn expected to speed push for SandRidge sale after board win

52m worldoil
The activist investor’s win on Tuesday installs a board expected to strongly market a company many investors would like to see broken up or sold off, said David Beard, a Coker & Palmer Inc. analyst in New Orleans. While the Oklahoma City-based driller has already disclosed contacts with potential bidders, Icahn has labeled those efforts a “ sham.”
MPO MPOYQ

20
SandRidge Approached by 17 Suitors, Icahn says Not to Bid Soon

2018-06-15 rigzone
June 15 (Reuters) - SandRidge Energy Inc said on Friday it had been approached by 17 potential bidders for a buyout, including billionaire Carl Icahn who is fighting for control of the oil and gas producer's board.
SDOCQ SDRPQ MPO DVN TRI MRO MPOYQ BCEI SDRXP SD SDRXQ

19
SandRidge Says Approached by 17 Potential Buyers, Including Icahn

2018-06-15 rigzone
June 15 (Reuters) - SandRidge Energy Inc said on Friday it had been approached by 17 potential bidders for a buyout, including billionaire Carl Icahn who is fighting for control of the oil and gas producer's board.
SDOCQ SDRPQ MPO DVN MRO MPOYQ BCEI SDRXP SD SDRXQ

19
UPDATE 3-SandRidge says approached by 17 potential buyers, including Icahn

2018-06-15 reuters
(Reuters) - SandRidge Energy Inc (SD.N) said on Friday it had been approached by 17 potential bidders for a buyout, including billionaire Carl Icahn who is fighting for control of the oil and gas producer’s board.
SDOCQ SDRPQ MPO DVN MRO MPOYQ BCEI SDRXP SD SDRXQ

14
SandRidge says approached by 17 potential buyers, including Icahn

2018-06-15 channelnewsasia
REUTERS: SandRidge Energy Inc said on Friday it had been approached by 17 potential bidders for a buyout, including billionaire Carl Icahn who is fighting for control of the oil and gas producer's board.
SDOCQ SDRPQ MPO MPOYQ BCEI SDRXP SD SDRXQ

14
Carl Icahn to Push for Full Board Refresh at SandRidge - WSJ

2018-04-05 wsj
Carl Icahn intends to nominate a full slate of candidates to the board of SandRidge Energy Inc., SD -0.74% saying that the current board’s overseeing a strategic review “is likely to be value destructive.”
SDOCQ SDRPQ MPO MPOYQ BCEI SDRXP SD SDRXQ

14
Carl Icahn Will Nominate Full Sandridge Board Slate - Bloomberg

2018-04-05 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
SDOCQ SDRPQ MPO MPOYQ BCEI SDRXP SD SDRXQ

94
Oil & Gas Stock Roundup: Shell's Iraq Sale, Apache's North Sea Find & More

2018-03-27 zacks
It was a week where oil rebounded to levels not seen since January but natural gas futures settled down further.
ITOCY APA BRGYY RDS.B RDS.A TXN SDRPQ RDSB RDSA SD BMI COP BG BHI BRGXF SDOCQ ITOCF RYDBF MPO MPOYQ RYDAF SDRXP SDRXQ

14
For Some Wounded US Drillers, the Oil Rout Never Ended

2018-03-27 rigzone
(Bloomberg) -- More than a year after exiting bankruptcy, SandRidge Energy Inc. is stuck in stock-market purgatory.
SDOCQ UPL SDRPQ MPO UPLMQ MPOYQ BCEI SDRXP SD SDRXQ

8
For some wounded American drillers, the oil rout never ended

2018-03-27 worldoil
The oil and gas explorer has seen its stock sink 37% since October 2016, despite a restructuring that wiped out $4 billion in debt. Activist investor Carl Icahn is threatening a proxy fight, and last week SandRidge rejected a merger that would have valued the once $11-billion company at just $589 million.
UPL MPO UPLMQ MPOYQ BCEI

37
SandRidge (SD) Nixes Merger Plan With Midstates Petroleum

2018-03-21 zacks
SandRidge Energy, Inc. (SD - Free Report) , an oil and gas player, recently aborted plans to merge with Tulsa-based rival Midstates Petroleum Company, in an all-stock deal. Last month, Midstates Petroleum had made the proposal to merge with SandRidge after the latter dropped its plan to acquire Colorado-based Bonanza, Creek Energy, Inc. (BCEI - Free Report) following intense opposition from its shareholders.
SDRPQ CTLR MS.PRE MS.PRF MS.PRG MS.PRA SD SDOCQ MS.PRI MS.PRK MPO MPOYQ CLR MS SDRXP SDRXQ

4
BlackBerry and SandRidge climb while Facebook dips

2018-03-20 nzherald.co.nz
The energy company rejected a buyout offer from Midstates Petroleum but said it will consider other offers.
MPO MPOYQ

38
Deals of the day-Mergers and acquisitions

2018-03-20 reuters
March 20 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1400 GMT on Tuesday:
ESLT GD RIO RIO SDRPQ CACI MDR CSRA SD SDOCQ RTPPF RIO RTNTF MPO MPOYQ SDRXP MCDFF SDRXQ

29
Deals of the day-Mergers and acquisitions

2018-03-20 reuters
March 20 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1030 GMT on Tuesday:
ESLT RIO RIO SDRPQ MDR SD SDOCQ RTPPF RIO RTNTF MPO MPOYQ SDRXP MCDFF SDRXQ

14
SandRidge rejects Midstates buyout offer, explores strategic options

2018-03-19 reuters
(Reuters) - Oil and gas producer SandRidge Energy Inc (SD.N) said on Monday it rejected smaller rival Midstates Petroleum Co Inc’s (MPO.N) offer to buy the company in an all-stock deal.
SDOCQ SDRPQ MPO MPOYQ BCEI SDRXP SD SDRXQ

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 59804T100